A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia
A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Yusha Zhu, M.D., Ph.D.
- 電話番号:646-725-2552
- メール:yusha.zhu@kindpharma.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Capable of providing signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
-
Body weight from 45-140 kg inclusive.
-
A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by eGFR <60 mL/min/1.73 m2.
-
Prior ESA use and Hb levels:
- ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and <10.0 g/dL.
- ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
-
TSAT ≥20% or ferritin ≥100 ng/mL at screening test.
-
Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test
-
Total bilirubin ≤1.5× upper limit normal (ULN). For Gilbert's Syndrom, <3×ULN.
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN
-
No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia
-
No other primary cause for anemia other than CKD.
Exclusion Criteria:
- Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
- Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms.
- History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
- Clinically significant bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
- History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
- Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
- History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
- Participants with a history of significant liver disease or active liver disease.
- History of a seizure disorder or any occurrence of seizures in the past.
- History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
- History of a seizure disorder or any occurrence of seizures in the past.
- History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
- Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
- Participants that have major surgery planned during the study period.
- Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
- Serum albumin (ALB) < 2.5 g/dL at screening test.
- Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody at the screening assessment, or positive for human immunodeficiency virus in a past test.
- Having received any investigational drug in an interventional clinical trial within 5 weeks before the randomization.
- A known history of allergic reactions to ESA treatment.
- History of serious drug allergies.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:AND017
|
AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients |
|
アクティブコンパレータ:ESA
|
ESA injection and dose based on package insert and local practice |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The mean Hb levels averaged over Week 25-29
時間枠:Week 25 to Week 29
|
Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD |
Week 25 to Week 29
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of responders over the main treatment period
時間枠:Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb < 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29 |
Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29
時間枠:Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29 |
Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
The percentage of response visits over the entire study treatment
時間枠:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL |
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
The cumulative incidence of Hb non-response over Weeks 5-29
時間枠:Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
Non-response is defined as Hb < 10.0 g/dL and an increase from baseline < 1.0 g/dL |
Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
|
|
Change from baseline in serum iron over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in ferritin over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in transferrin over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in transferrin saturation over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in total iron binding capacity over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
The percentage of patients received intravenous iron treatment during the entire study
時間枠:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)
時間枠:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)
時間枠:Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in total cholesterol over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in low density lipoprotein over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in high density lipoprotein over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
|
|
Change from baseline in triglycerides over the entire treatment period
時間枠:Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- AND017-US-303
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。